Fortis Healthcare Limited — Q2 FY26
Fortis Healthcare delivered a strong Q2 FY26 with consolidated revenue of INR 2,331 crore (+17.3% YoY) and EBITDA margin expansion of 200 bps to 23.9%.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
Hospital EBITDA margin improvement of ~200 bps for FY26
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
Diagnostics EBITDA margin of 22-23% for FY26
Management expects diagnostics EBITDA margins to remain in the 22-23% range for the full year, with Q2 typically stronger.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
Add ~900 beds in FY26, ~50% operationalized this year
Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1